{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:20:18Z","timestamp":1758979218715},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s00105-005-0946-1","type":"journal-article","created":{"date-parts":[[2005,4,6]],"date-time":"2005-04-06T10:17:25Z","timestamp":1112782645000},"page":"576-580","source":"Crossref","is-referenced-by-count":5,"title":["Gesundheits\u00f6konomische Aspekte der Psoriasistherapie"],"prefix":"10.1007","volume":"56","author":[{"given":"M.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"946_CR1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1610-0387.2003.03014.x","volume":"1","author":"Boehneke","year":"2003","unstructured":"Boehneke WH, Friedrich M, Mrowietz U et al. (2003) Stellenwert von Biologics in der Psoriais-Therapie: Ein Konsensus-Papier der Arbeitsgruppe Psoriasis, Arbeitsgemeinschaft dermatologische Forschung. JDDG 1:620\u2013628","journal-title":"JDDG"},{"key":"946_CR2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archderm.1965.01600130062010","volume":"92","author":"Comaish","year":"1965","unstructured":"Comaish S (1965) Ingram method of treating psoriasis. Arch Dermatol 92:56\u201358","journal-title":"Arch Dermatol"},{"key":"946_CR3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s001050050830","volume":"49","author":"Degitz","year":"1998","unstructured":"Degitz K, Messer G, Plewig G, R\u00f6cken M (1998) Schmalspektrum UV-B 311\u00a0nm versus Breitspektrum UV-B. Hautarzt 49:795\u2013806","journal-title":"Hautarzt"},{"key":"946_CR4","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","volume":"23","author":"Gordon","year":"2003","unstructured":"Gordon KB, Papp KA, Hamilton TK et al. (2003) Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 23:3073\u20133080","journal-title":"JAMA"},{"key":"946_CR5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"Lebwohl","year":"2003","unstructured":"Lebwohl M, Tyring SK, Hamilton TK et al. (2003) A novel targeted t-cell modulator, Efalizumab, for plaque psoriasis. N Engl J Med 349:2004\u20132013","journal-title":"N Engl J Med"},{"key":"946_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2004.03.015","volume":"22","author":"Leonardi","year":"2004","unstructured":"Leonardi CL (2004) Current concepts and reviews of Efalizumab in the treatment of psoriasis. Dermatol Clin 22:427\u2013435","journal-title":"Dermatol Clin"},{"key":"946_CR7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00105-003-0497-2","volume":"54","author":"Mrowietz","year":"2003","unstructured":"Mrowietz C (2003) Therapie der Psoriasis mit Biologicals. Hautarzt 54:224\u2013229","journal-title":"Hautarzt"},{"key":"946_CR8","first-page":"1047","volume":"55","author":"Richter","year":"2004","unstructured":"Richter L, Weber R, Doelfs P et al. (2004) Station\u00e4re Behandlungskosten von Hautkrankheiten. Hautarzt 55:1047\u20131051","journal-title":"Hautarzt"},{"key":"946_CR9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2001-14534","volume":"27","author":"Sander","year":"2001","unstructured":"Sander P, St\u00fccker M, Hoffmann M et al. (2001) Topische Dreifach-Therapie der chronisch station\u00e4ren Psoriasis (CSP). Akt Dermatol 27:173\u2013177","journal-title":"Akt Dermatol"},{"key":"946_CR10","first-page":"775","volume":"42","author":"Scholz","year":"1991","unstructured":"Scholz V, Kadner H (1991) 75\u00a0Jahre Cignolin. Hautarzt 42:775\u2013778","journal-title":"Hautarzt"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-005-0946-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0946-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:05Z","timestamp":1558568225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-005-0946-1"}},"subtitle":["Ist die station\u00e4r durchgef\u00fchrte Lokaltherapie der Psoriasis vulgaris vom Plaquetyp im Zeitalter moderner Biologics unter Ber\u00fccksichtigung medizinischer und \u00f6konomischer Gesichtspunkte noch vertretbar?"],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s00105-005-0946-1","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}